Oral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides), By End Users (Hospitals, Homecare, Speciality Centers, Others) By Region a

Market Overview

Key Market Drivers

Increasing Global Diabetes Prevalence

Advancements in Drug Formulations

Increasing Awareness and Diagnosis

Expanding Geriatric Population

Key Market Challenges

High Healthcare Costs

Side Effects and Safety Concerns

Medication Adherence

Key Market Trends

Personalized Medicine Approaches

Regulatory Support and Expedited Approvals

Innovations in Drug Formulations

Segmental Insights

Drugs Insights

Regional Insights

Recent Developments

• Zydus Lifesciences declared inJuly 2022 that it has been granted approval to market tablets of metforminhydrochloride and empagliflozin in various strengths. To enhance glycemiccontrol in individuals with type 2 diabetes mellitus, empagliflozin and metforminhydrochloride tablets are taken in conjunction with a healthy diet andexercise. In individuals with type 2 diabetes mellitus and establishedcardiovascular disease, they are also used to reduce the risk of cardiovasculardeath.
• In July 2022, GlenmarkPharmaceuticals Limited declared that sitagliptin and its Fixed DoseCombinations (FDCs) were now available in India for adults with Type 2diabetes. Under the brand name SITAZIT and its variations, Glenmark madeavailable eight alternative combinations of sitagliptin-based medications for areasonable price.

Key Market Players

• KONINKLIJKEPHILIPS N.V.
• SanofiS.A.
• EliLilly and Company
• AstraZeneca
• AstellasPharma Inc.
• Johnson& Johnson (Janssen Pharmaceuticals)
• BoehringerIngelheim
• MerckAnd Co.
• BristolMyers Squibb Company
• NovartisAG